Trial Profile

Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients With Atrial Fibrillation and Rapid Ventricular Rate (RVR)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etripamil (Primary)
Indications Atrial fibrillation
Focus Registrational; Therapeutic Use
Acronyms ReVeRA-301
Sponsors Milestone Pharmaceuticals

Most Recent Events

02 Sep 2026 Last checked against Clinicaltrials.gov record.
21 Aug 2026 According to a milestone pharma media release, company activating clinical trial sites across North America and internationally to support efficient enrollment in global Phase 3 study.
21 Aug 2026 According to a milestone pharma media release, the first patient has been enrolled in the Phase 3 ReVeRA-301 pivotal trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com